Health Economics Increasingly Inputs into Clinical Development
Payer demand for value indicators that can guide compensation conclusions are prompting top pharmaceutical companies to increasingly request input into clinical development from their health economics department, according to a new study. While clinical data is fundamental in driving reimbursement decisions, companies that only evaluate finished clinical trial data to determine a product’s economic benefit